ESC Premium Access

Empagliflozin reduces mortality in analyses adjusted for control of blood pressure, low density lipoprotein cholesterol and HbA1c over time

Congress Presentation

About the speaker

Doctor David Fitchett

St. Michael's Hospital, Toronto (Canada)
16 presentations
0 follower

4 more presentations in this session

State of the Art: glucose-lowering drugs and cardiovascular outcomes

Speaker: Professor S. Anker (Berlin, DE)

Thumbnail

Heart failure with mid range ejection fraction, characteristics and prognosis in patients with and without type 2 diabetes

Speaker: Doctor I. Johansson (Stockholm, SE)

Thumbnail

How does diabetes affect iron status in patients with heart failure?

Speaker: Doctor M. Drozd (Wroclaw, PL)

Thumbnail

Heart failure and diabetes: lessons from the ESC long-term registry

Speaker: Professor O. Chioncel (Bucharest, RO)

Thumbnail

Access the full session

Heart failure and diabetes: a treacherous combination

Speakers: Doctor D. Fitchett, Professor S. Anker, Doctor I. Johansson, Doctor M. Drozd, Professor O. Chioncel
Thumbnail

About the event

Image

ESC CONGRESS 2017

26 August - 30 August 2017

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk